ArticlePloS one2026
Uralenol, Glycyrol, and Abyssinone II as potent inhibitors of fibroblast growth factor receptor 2 from anti-cancer plants: A deep learning and molecular dynamics approach.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibroblast Growth Factor Receptor 2 (FGFR2) plays a critical role in cellular proliferation and differentiation, and its dysregulation is associated with multiple cancers. This study integrates molecular docking, deep learning, pharmacokinetic profiling, and molecular dynamics (MD) simulations to identify potential FGFR2 inhibitors from a library of 1,350 phytochemicals derived from 51 anti-cancer medicinal plants that were traditionally used for anticancer purposes. Initial screening through AutoDock Vina revealed several top candidates with high binding affinities to FGFR2. The top three compounds, uralenol, glycyrol, and abyssinone II, underwent further evaluation via deep learning models, which predicted the potential efficacy of the pIC₅₀ (negative logarithm of the half-maximal inhibitory concentration) values. The ADME/T (absorption, distribution, metabolism, excretion, and toxicity) analysis confirmed favorable pharmacokinetic profiles and low toxicity risks. MD simulations validated the stability and compactness of protein-ligand complexes, with principal component analysis (PCA) and free energy landscape analyses confirming these interactions' conformational stability and thermodynamic favorability. These findings suggest that uralenol, glycyrol, and abyssinone II are potential FGFR2 inhibitors and need further experimental validation for potential therapeutic use in cancer treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.